Ligand Pharmaceuticals Insider John W. Kozarich Sells $162K of Stock
John W. Kozarich sold 500 shares of Ligand Pharmaceuticals Inc at $325.00 a share, worth $162K in total on Nov 12, 2026. Shares held after the trade: 42,122 (-1.2%).
Ligand Pharmaceuticals Insider Martine Zimmermann Sells $636K of Stock
Martine Zimmermann sold 2,000 shares of Ligand Pharmaceuticals Inc at $318.17 a share, worth $636K in total on Nov 12, 2026. Shares held after the trade: 1,782 (-52.9%).
Ligand Pharmaceuticals Insider Jason Aryeh Sells $957K of Stock
Jason Aryeh sold 2,990 shares of Ligand Pharmaceuticals Inc at $319.99 to $320.20 a share (average $320.05) in 5 transactions, worth $957K in total on Nov 10, 2026. Shares held after the trade: 105,476 (-0.5%).
Ligand Pharmaceuticals Insider Jason Aryeh Sells $90.2K of Stock
Jason Aryeh sold 282 shares of Ligand Pharmaceuticals Inc at $319.99 a share, worth $90.2K in total on Nov 4, 2026. Shares held after the trade: 108,476 (-0.3%).
Ligand Pharmaceuticals CLO & Secretary Andrew Reardon Sells $1.57M of Stock
Andrew Reardon, CLO & Secretary, sold 5,000 shares of Ligand Pharmaceuticals Inc at $307.39 to $323.14 a share (average $313.22) in 13 transactions, worth $1.57M in total on Nov 2, 2026. Shares held after the trade: 31,854 (-0.4%).
Ligand Pharmaceuticals Insider Jason Aryeh Sells $676K of Stock
Jason Aryeh sold 2,111 shares of Ligand Pharmaceuticals Inc at $317.74 to $320.49 a share (average $320.30) in 6 transactions, worth $676K in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 108,758 (-0.6%).
For the nine months ended September 30, 2026, Ligand Pharmaceuticals reported total revenues and income of $194.2 million and net income of $6.7 million, a decrease from $79.7 million in the prior year period. The company significantly expanded its balance sheet through the acquisition of XOMA, resulting in total assets increasing to $2.24 billion compared to $1.56 billion at year-end 2025.
Ligand Pharmaceuticals reported Q3 2026 financial results, highlighted by a 51% year-over-year increase in royalty revenue to $70.3 million, driven by the XOMA portfolio and commercial momentum of Filspari. The company raised its full-year 2026 adjusted diluted EPS guidance to a range of $9.50 to $9.75 while reaffirming its total revenue guidance.
Term
Q3 2026
“Ligand delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalty assets, including Filspari.”
Ligand Pharmaceuticals CLO & Secretary Andrew Reardon Sells $1.52M of Stock
Andrew Reardon, CLO & Secretary, sold 4,983 shares of Ligand Pharmaceuticals Inc at $302.51 to $307.19 a share (average $304.06) in 5 transactions, worth $1.52M in total on Oct 2, 2026. Shares held after the trade: 31,871 (-0.7%).
Ligand Pharmaceuticals Signs $23M M&A Deal with Sydnexis, Inc.
Ligand Pharmaceuticals acquired royalty and milestone payment rights for Ryjunea from Sydnexis for $23 million upfront. Ryjunea is a treatment for pediatric myopia licensed to Santen Pharmaceutical in the EMEA region, where it is already approved. Ligand will receive tiered royalties ranging from low-double-digits to high-teens on net sales in those territories.
Ligand Pharmaceuticals Insider Martine Zimmermann Sells $342K of Stock
Martine Zimmermann sold 1,200 shares of Ligand Pharmaceuticals Inc at $285.00 a share, worth $342K in total on Sep 10, 2026. Shares held after the trade: 3,897 (-23.5%).